Pharmaniaga

Pharmaniaga was established in 1994 as Remedi Pharmaceuticals.[1] The company was renamed as Pharmaniaga in August 1998 and is the first healthcare company in Malaysia to be listed in the Main Market of Kuala Lumpur Stock Exchange (now Bursa Malaysia).[2]

Pharmaniaga is one of Malaysia’s largest integrated pharmaceutical groups with a firm focus on protecting the nation via providing accessible and affordable healthcare solutions, with operations in Malaysia and Indonesia.

It is involved in various segments of the pharmaceutical value chain, including research and development, manufacturing of generic drugs and medical devices, logistics and distribution, sales and marketing, as well as community pharmacy.

Pharmaniaga has over 3,600 employees, and is home to more than 300 scientists, including researchers, chemists, pharmacologists, formulators, IT engineers, regulatory affairs and clinical affairs specialists.

It has an extensive pharmaceutical logistics and distribution network in Malaysia with four warehouses equipped with pharma-grade cold rooms and delivers drugs as well as medical equipment to almost 10,000 health facilities nationwide.

With seven manufacturing plants, Pharmaniaga is capable of producing products in various forms; from oral solids, liquids and creams to small volume injectables.  Its product portfolio encompasses a diverse segment of therapeutic areas such as cardiovascular, anti-diabetic, antibiotics, antivirals, over the counter products and nutraceuticals, amongst others.

Its Indonesia operations include a general pharma manufacturing plant and a public listed pharmaceutical logistics and distribution company with 33 branches throughout the republic.

In 2021, during the Coronavirus pandemic, Pharmaniaga was appointed as the Malaysian distributor for Sinovac CoronaVac vaccine. Its high-tech European Union-certified plant manufactures fill and finish Sinovac COVID-19 vaccine. Through the supply, as well as fill and finish manufacturing of Sinovac COVID-19 vaccine, we were able to assist Malaysia in its effort to combat the virus. Its employees worked around the clock to protect the nation by supplying, manufacturing and delivering the Sinovac COVID-19 vaccine to all corners of the country. 20.4 million doses of the vaccine was delivered to the Government, four months ahead of schedule. This had indeed accelerated the National COVID-19 Immunisation Programme and enabled Malaysia to be amongst the countries with the fastest vaccination rate in the world.

Pharmaniaga is a public limited company. As at 31 January 2022, Boustead Holdings owns 51.845% of the company, while Lembaga Tabung Angkatan Tentera (LTAT) owns 9.352%. The major owner of Boustead Holdings is itself LTAT.

As at August 2021, the board of directors of Pharmaniaga are Datuk Seri Zainal Abidin Mohd Rafique who serves as the Chairman, Datuk Zulkarnain Md Eusope as the Group Managing Director, Zulkifli Jafar as Group Executive Director and Mohamed Iqbal Abdul Rahman as the Group Deputy Managing Director. The company's Independent Non-Executive Directors are Dato' Dr. Najmil Faiz Mohamed Aris, Datuk Dr. Azhar Ahmad, Dr. Abdul Razak Ahmad and Sarah Azreen Abdul Samat while Izaddeen Daud is its Non-Independent Non-Executive Director.